At the Supreme Court: What’s at Stake for Emergency Abortion Care?
On April 24, the Supreme Court will hear Idaho v. United States—the second case this term involving access to abortion.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →
On April 24, the Supreme Court will hear Idaho v. United States—the second case this term involving access to abortion.
On April 24, 2024, the Supreme Court will hear the second case this term involving access to abortion: Idaho v. United States. At stake in this case is whether the Emergency Medical Treatment and Active Labor Act, a federal law requiring hospitals to provide stabilizing treatment to patients who present to their emergency rooms, preempts state abortion laws and requires hospitals that accept Medicare to provide abortion care when it is necessary to stabilize a patient’s condition, even when this abortion care violates state law.
In a new brief, KFF examines how the Comstock Act, an 1873 anti-vice law banning the mailing of obscene matter and articles, could be used by an anti-abortion presidential administration to sharply restrict the availability of abortion nationwide.
This brief provides background on the Comstock Act, reviews how it has been interpreted by the Biden Administration’s DOJ, and considers how it could be enforced by an administration that is hostile toward abortion to severely restrict the distribution of drugs and supplies used for abortion, with implications for abortion access in all states across the country.
According to new KFF polling, in states with abortion bans, one in five (21%) women of reproductive age (18 to 49) and one in seven (14%) of all women say either they or someone they know has had difficulty accessing an abortion since the Supreme Court overturned Roe v. Wade.
Our latest poll finds one in five women of reproductive age in states with abortion bans say either they or someone they personally know has had difficulty obtaining an abortion. Majorities of women across states—including in those with abortion bans—think abortion should be legal in all or most cases and support a range of policies that protect abortion access.
This brief looks at Medicaid reimbursement rates for abortion services across states, including D&C and D&E procedures, and medication abortion. There is tremendous variability in how much states reimburse for abortion services.
In advance of oral arguments about access to medication abortion before the Supreme Court on March 26, KFF examines how a Court ruling for the plaintiffs would limit access to mifepristone blocking its use in telehealth and distribution through pharmacies, including in states where abortion is legal and protected.
The Supreme Court will be hearing oral arguments for the case FDA v. Alliance for Hippocratic Medicine. This brief explains the issues at stake before the court and their implications for the drug regulatory process and medication abortion access throughout the country.
This factsheet provides an overview of medication abortion, with a focus on federal and state regulations pertaining to its provision and coverage, and the role of the drug in self-managed abortions.
© 2026 KFF
